000272852 001__ 272852
000272852 005__ 20241029085454.0
000272852 0247_ $$2doi$$a10.1002/mds.29879
000272852 0247_ $$2pmid$$apmid:38847384
000272852 0247_ $$2ISSN$$a0885-3185
000272852 0247_ $$2ISSN$$a1531-8257
000272852 0247_ $$2altmetric$$aaltmetric:164390137
000272852 037__ $$aDZNE-2024-01270
000272852 041__ $$aEnglish
000272852 082__ $$a610
000272852 1001_ $$0P:(DE-2719)9003066$$aJensen, Ida Marie Louise$$b0$$udzne
000272852 245__ $$aImpact of Magnetic Resonance Imaging Markers on the Diagnostic Performance of the International Parkinson and Movement Disorder Society Multiple System Atrophy Criteria.
000272852 260__ $$aNew York, NY$$bWiley$$c2024
000272852 3367_ $$2DRIVER$$aarticle
000272852 3367_ $$2DataCite$$aOutput Types/Journal article
000272852 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1729780484_26451
000272852 3367_ $$2BibTeX$$aARTICLE
000272852 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000272852 3367_ $$00$$2EndNote$$aJournal Article
000272852 520__ $$aMultiple system atrophy is a neurodegenerative disease with α-synuclein aggregation in glial cytoplasmic inclusions, leading to dysautonomia, parkinsonism, and cerebellar ataxia.The aim of this study was to validate the accuracy of the International Parkinson and Movement Disorder Society Multiple System Atrophy clinical diagnostic criteria, particularly considering the impact of the newly introduced brain magnetic resonance imaging (MRI) markers.Diagnostic accuracy of the clinical diagnostic criteria for multiple system atrophy was estimated retrospectively in autopsy-confirmed patients with multiple system atrophy, Parkinson's disease, progressive supranuclear palsy, and corticobasal degeneration.We identified a total of 240 patients. Sensitivity of the clinically probable criteria was moderate at symptom onset but improved with disease duration (year 1: 9%, year 3: 39%, final ante mortem record: 77%), whereas their specificity remained consistently high (99%-100% throughout). Sensitivity of the clinically established criteria was low during the first 3 years (1%-9%), with mild improvement at the final ante mortem record (22%), whereas specificity remained high (99%-100% throughout). When MRI features were excluded from the clinically established criteria, their sensitivity increased considerably (year 1: 3%, year 3: 22%, final ante mortem record: 48%), and their specificity was not compromised (99%-100% throughout).The International Parkinson and Movement Disorder Society multiple system atrophy diagnostic criteria showed consistently high specificity and low to moderate sensitivity throughout the disease course. The MRI markers for the clinically established criteria reduced their sensitivity without improving specificity. Combining clinically probable and clinically established criteria, but disregarding MRI features, yielded the best sensitivity with excellent specificity and may be most appropriate to select patients for therapeutic trials. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
000272852 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000272852 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x1
000272852 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000272852 650_7 $$2Other$$aMRI
000272852 650_7 $$2Other$$aautopsy‐confirmed
000272852 650_7 $$2Other$$abrain magnetic resonance imaging
000272852 650_7 $$2Other$$amultiple system atrophy
000272852 650_2 $$2MeSH$$aHumans
000272852 650_2 $$2MeSH$$aMultiple System Atrophy: diagnostic imaging
000272852 650_2 $$2MeSH$$aMultiple System Atrophy: diagnosis
000272852 650_2 $$2MeSH$$aFemale
000272852 650_2 $$2MeSH$$aMale
000272852 650_2 $$2MeSH$$aAged
000272852 650_2 $$2MeSH$$aMiddle Aged
000272852 650_2 $$2MeSH$$aParkinson Disease: diagnostic imaging
000272852 650_2 $$2MeSH$$aParkinson Disease: diagnosis
000272852 650_2 $$2MeSH$$aMagnetic Resonance Imaging: standards
000272852 650_2 $$2MeSH$$aMagnetic Resonance Imaging: methods
000272852 650_2 $$2MeSH$$aRetrospective Studies
000272852 650_2 $$2MeSH$$aSupranuclear Palsy, Progressive: diagnostic imaging
000272852 650_2 $$2MeSH$$aSensitivity and Specificity
000272852 650_2 $$2MeSH$$aBrain: diagnostic imaging
000272852 650_2 $$2MeSH$$aBrain: pathology
000272852 650_2 $$2MeSH$$aAged, 80 and over
000272852 7001_ $$aHeine, Johanne$$b1
000272852 7001_ $$aRuf, Viktoria C$$b2
000272852 7001_ $$aCompta, Yaroslau$$b3
000272852 7001_ $$aPorcel, Laura Molina$$b4
000272852 7001_ $$aTroakes, Claire$$b5
000272852 7001_ $$aVamanu, Albert$$b6
000272852 7001_ $$aDownes, Sophia$$b7
000272852 7001_ $$aIrwin, David$$b8
000272852 7001_ $$00000-0003-2554-5181$$aCohen, Jesse$$b9
000272852 7001_ $$aLee, Edward B$$b10
000272852 7001_ $$aNilsson, Christer$$b11
000272852 7001_ $$aEnglund, Elisabet$$b12
000272852 7001_ $$0P:(DE-2719)9002938$$aNemati, Mojtaba$$b13$$udzne
000272852 7001_ $$0P:(DE-2719)9001160$$aKatzdobler, Sabrina$$b14$$udzne
000272852 7001_ $$0P:(DE-2719)2811659$$aLevin, Johannes$$b15$$udzne
000272852 7001_ $$00000-0002-6427-7485$$aPantelyat, Alex$$b16
000272852 7001_ $$aSeemiller, Joseph$$b17
000272852 7001_ $$aBerger, Stephen$$b18
000272852 7001_ $$avan Swieten, John$$b19
000272852 7001_ $$aDopper, Elise$$b20
000272852 7001_ $$aRozenmuller, Annemieke$$b21
000272852 7001_ $$aKovacs, Gabor G$$b22
000272852 7001_ $$00000-0003-2167-5667$$aBendahan, Nathaniel$$b23
000272852 7001_ $$aLang, Anthony E$$b24
000272852 7001_ $$0P:(DE-2719)2810441$$aHerms, Jochen$$b25$$udzne
000272852 7001_ $$0P:(DE-2719)2811373$$aHöglinger, Günter$$b26
000272852 7001_ $$0P:(DE-2719)9003372$$aHopfner, Franziska$$b27$$udzne
000272852 773__ $$0PERI:(DE-600)2041249-6$$a10.1002/mds.29879$$gVol. 39, no. 9, p. 1514 - 1522$$n9$$p1514 - 1522$$tMovement disorders$$v39$$x0885-3185$$y2024
000272852 8564_ $$uhttps://pub.dzne.de/record/272852/files/DZNE-2024-01270.pdf$$yOpenAccess
000272852 8564_ $$uhttps://pub.dzne.de/record/272852/files/DZNE-2024-01270.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000272852 909CO $$ooai:pub.dzne.de:272852$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000272852 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9003066$$aExternal Institute$$b0$$kExtern
000272852 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9002938$$aExternal Institute$$b13$$kExtern
000272852 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9001160$$aExternal Institute$$b14$$kExtern
000272852 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811659$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b15$$kDZNE
000272852 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810441$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b25$$kDZNE
000272852 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811373$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b26$$kDZNE
000272852 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9003372$$aExternal Institute$$b27$$kExtern
000272852 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000272852 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x1
000272852 9141_ $$y2024
000272852 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-24
000272852 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-24
000272852 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-24
000272852 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-24
000272852 915__ $$0LIC:(DE-HGF)CCBYNCND4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
000272852 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOVEMENT DISORD : 2022$$d2023-10-24
000272852 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2023-10-24$$wger
000272852 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-24
000272852 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-24
000272852 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000272852 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-24
000272852 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bMOVEMENT DISORD : 2022$$d2023-10-24
000272852 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-24
000272852 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-24
000272852 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-24$$wger
000272852 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-24
000272852 9201_ $$0I:(DE-2719)1110002$$kAG Höglinger$$lTranslational Neurodegeneration$$x0
000272852 9201_ $$0I:(DE-2719)1110001$$kAG Herms$$lTranslational Brain Research$$x1
000272852 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x2
000272852 980__ $$ajournal
000272852 980__ $$aVDB
000272852 980__ $$aUNRESTRICTED
000272852 980__ $$aI:(DE-2719)1110002
000272852 980__ $$aI:(DE-2719)1110001
000272852 980__ $$aI:(DE-2719)1111015
000272852 9801_ $$aFullTexts